Colleen Silk/LinkedIn
Nov 4, 2025, 08:22
Colleen Silk on Novo Nordisk Taking the 2025 Prix Galien US Award
Colleen Silk, Corporate Vice President, Rare Disease at Novo Nordisk, shared on LinkedIn:
”Rare diseases remind us that science must never overlook the few.
Hemophilia B with inhibitors affects only a small number of people, yet its impact is profound.
We are proud to have been recognized as a finalist for the 2025 Prix Galien US Award for Best Orphan/Rare Disease Product.
Novo Nordisk believes that every person—no matter how rare their condition—deserves the best that science can offer.
We’re proud of this recognition and grateful to the Prix Galien Foundation for honoring innovation that makes a real difference.”
More winner stories featured in Hemostasis Today.
-
Apr 3, 2026, 05:59Nathan Connell: How the 2021 VWD Guidelines Are Actually Changing Real – World Practice
-
Apr 3, 2026, 05:28Tareq Abadl: How Iron Profile Reveals Hidden Insights about Blood Health and Iron Balance
-
Apr 3, 2026, 04:49Niraj Sharma: Breaking News Special Edition, CHAMPION-AF, CLOSURE-AF, PRAGUE-17, and Why LAAC Still Does Not Dethrone Contemporary Anticoagulation
-
Apr 2, 2026, 18:32Niyas Khalid: A Rare Case of Venous Ischemic Pancreatitis Redefining Diagnosis
-
Apr 2, 2026, 18:16Saravanan Subramaniam: How Extracellular Histones Act as Key Drivers of Thromboinflammation
-
Apr 2, 2026, 18:06Rob Molhoek Brings Invaluable Insights on Stroke Awareness and Care Improvements – Stroke Foundation
-
Apr 2, 2026, 17:21Paul Bolaji: Phase 2 of the Nigeria National Stroke Registry Is Now Live
-
Apr 2, 2026, 17:13Catherine Jennings: Marking Today as an Important Step Forward for Patients With PE
-
Apr 2, 2026, 17:11Arun V. J: Our Clinical Audit on Transfusion Safety Selected for Presentation at CAHOCON 2026